FindTrial
Sign In

Effect of neoadjuvant chemotherapy combined with radiotherapy on postoperative lars of rectal cancer: a prospective cohort study

Whether neoadjuvant chemotherapy combined radiotherapy for colorectal cancer postoperative LARS: prospective cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000041137
Enrollment
Unknown
Registered
2020-12-19
Start date
2020-07-31
Completion date
Unknown
Last updated
2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low anterior resection syndrome

Interventions

neoadjuvant chemoradiotherapy:Nil
neoadjuvant chemotherapy:Nil

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1. Patients with rectal malignant tumors (including adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma) diagnosed by pathology should be less than 18cm from the dentate line; 2. Patients who received tumor resection for the first time; 3. Patients receiving neoadjuvant therapy before operation; 4. Patients aged 18-95 years old; 5. Patients with informed consent and their families voluntarily participated in this study; 6. Subjects who can understand and correctly express Chinese.

Exclusion criteria

Exclusion criteria: 1. Patients admitted to emergency department; 2. Patients with metastatic or recurrent cancer; 3. Patients with squamous cell carcinoma, basal cell carcinoma of skin or tumors of unknown nature; 4. Patients who underwent surgery without neoadjuvant therapy.

Design outcomes

Primary

MeasureTime frame
LARS score;—

Countries

China

Contacts

Public ContactLi Li

West China Hospital of Sichuan University

drlili116@126.com+86 18980601487

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026